CAR-T Therapy Shows Promise for Stiff Person Syndrome
A small clinical trial led by Mayo Clinic in Rochester found the cell therapy restored everyday function in patients with the rare neurological disorder.
Updated on Nov. 9, 2026 in Stroke

A clinical trial reports that CAR-T cell therapy produced dramatic improvements in people with stiff person syndrome, a rare and progressively worsening neurological disorder. Two trial patients regained everyday function that the condition had taken away.
Why it matters
Stiff person syndrome is thought to be an autoimmune condition in which the immune system attacks healthy cells by mistake, and it has no widely established cure. The results suggest an approach already used for some cancers may be explored for this disorder, which affects an estimated 8,000 people worldwide.
The findings rest on results from a small trial of two patients published in JAMA Neurology, against a condition estimated to affect 8,000 people worldwide. Whether the benefits will last over time has not yet been determined.
The players
Mayo Clinic
Mayo Clinic is a major academic medical center based in Rochester, Minnesota, that led this clinical trial.
Celine Dion
Celine Dion is a Canadian singer who publicly disclosed in December 2022 that she had been diagnosed with stiff person syndrome.
The details
Patients received a one-off CAR-T cell therapy infusion, a treatment that teaches the immune system to recognise and attack disease-causing cells. Jonathan Walden returned to work and hunting and fishing after treatment, and Shari St Germain, diagnosed in 2021, reported walking on a treadmill for seven minutes after standard treatments stopped controlling her symptoms in 2024.
Timeline
2021: Shari St Germain is diagnosed with stiff person syndrome.
2022: Celine Dion publicly reveals her stiff person syndrome diagnosis.
2024: Standard treatments stop controlling St Germain's symptoms.
November 9, 2026: The trial results are published in JAMA Neurology.
Medical Landscape
CAR-T cell therapy is already approved on the NHS for certain cancers, and this trial extends the same immune-targeting approach into an autoimmune neurological disorder. The result marks an early step in testing whether that cancer-based model can apply to conditions that have few effective long-term options.
For people living with stiff person syndrome, the trial offers a possible new treatment path where standard therapies have stopped working. Any future availability would depend on larger studies confirming the benefit and its durability.
The takeaway
A small trial showing meaningful gains is an early signal rather than proof, and the durability of these results will determine whether CAR-T therapy becomes a practical option for stiff person syndrome.
What happens next
Researchers say the study could lead to larger trials in people with stiff person syndrome, though no dates for those trials have been announced.
Further reading
For more on neurological conditions, see the Stroke section.










